Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 1 diabetes.~* Patients aged 12-18 years with at least 5 years disease duration.~* Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[UAE\] 30-299 mg/g creatinine in two of three samples over a 3- to 6- months period despite angiotensin converting enzyme inhibitors)~* Hemoglobin A1c (HbA1c) ≤8.5%~* Patients on regular visit to clinic.~* Patients on regular insulin therapy.~Exclusion Criteria:~Patients were excluded if they have any of the following:~* Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes.~* Patients with any evidence of renal impairment due to cause other than diabetes.~* Patients with hypertension.~* Hepatitis virus infection (B or C) or any evidence of infection.~* Taking any vitamins or food supplements one month before study.~* Participation in a previous investigational drug study within 3 months preceding screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: ACTIVE_COMPARATOR): Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
- Control group (Type: PLACEBO_COMPARATOR): Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .

Based on this trial design, predict the completion outcome and termination type (if applicable).